Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Chief Scientific Officer | January 22, 2026 | January 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date January 22, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,477 |
Ending reported balance
After 2026-01-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-22 · Grant · Acquired 7,866 · Balance 31,149 F1: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. Row 2 · 2026-01-22 · Grant · Acquired 3,328 · Balance 34,477 F2: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.
F2: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2015 Filed Dec 4, 2015 02:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-15-083420 · doc4.xml · derivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 5,000 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| December 01, 2015 Filed Dec 4, 2015 02:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,000 | $131.00 | $655,000.00 |
DisclosureSEC source: 0001209191-15-083420 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| December 01, 2015 Filed Dec 4, 2015 02:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,000 | $72.14 | $360,700.00 |
DisclosureSEC source: 0001209191-15-083420 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2015 Filed Nov 20, 2015 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $63.14 | $0.00 |
DisclosureSEC source: 0001209191-15-081510 · doc4.xml · derivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 05/24/2012. Read SEC document |
| November 18, 2015 Filed Nov 20, 2015 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-15-081510 · doc4.xml · derivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 7,500 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 18, 2015 Filed Nov 20, 2015 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 15,000 | $130.00 | $1,950,000.00 |
DisclosureSEC source: 0001209191-15-081510 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 18, 2015 Filed Nov 20, 2015 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $63.14 | $473,550.00 |
DisclosureSEC source: 0001209191-15-081510 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2015 Filed Nov 20, 2015 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $72.14 | $541,050.00 |
DisclosureSEC source: 0001209191-15-081510 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2015 Filed Jul 23, 2015 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-15-062167 · doc4.xml · derivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2025-07-20 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/21/2015. Read SEC document |
| January 12, 2015 Filed Jan 13, 2015 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 75,000 | $0.01 | $750.00 |
DisclosureSEC source: 0001209191-15-003883 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F1 · shares: Performance-based retention award that will vest if performance objectives are achieved prior to November 15, 2019. The award will vest on January 12, 2018 if the Company achieves positive EBITDA for the 12-month period ending September 30, 2017. Between January 13, 2018 and November 15, 2019, if the Company achieves positive EBITDA for a 12-month period ending on a calendar quarter, the award will vest on the day following the applicable earnings release. Read SEC document |
| November 28, 2014 Filed Dec 1, 2014 22:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $59.55 | $0.00 |
DisclosureSEC source: 0001209191-14-071964 · doc4.xml · derivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| November 28, 2014 Filed Dec 1, 2014 22:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $63.14 | $0.00 |
DisclosureSEC source: 0001209191-14-071964 · doc4.xml · derivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 1,000 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 05/24/2012. Read SEC document |
| November 28, 2014 Filed Dec 1, 2014 22:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,500 | $119.75 | $419,125.00 |
DisclosureSEC source: 0001209191-14-071964 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 28, 2014 Filed Dec 1, 2014 22:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,500 | $59.55 | $148,875.00 |
DisclosureSEC source: 0001209191-14-071964 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2014 Filed Dec 1, 2014 22:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,000 | $63.14 | $63,140.00 |
DisclosureSEC source: 0001209191-14-071964 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2014 Filed Oct 30, 2014 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $63.14 | $0.00 |
DisclosureSEC source: 0001209191-14-065392 · doc4.xml · derivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 2,000 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 05/24/2012. Read SEC document |
| October 28, 2014 Filed Oct 30, 2014 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,000 | $114.75 | $229,500.00 |
DisclosureSEC source: 0001209191-14-065392 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 28, 2014 Filed Oct 30, 2014 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,000 | $63.14 | $126,280.00 |
DisclosureSEC source: 0001209191-14-065392 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2014 Filed Oct 8, 2014 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,405 | $0.00 Strike: $63.14 | $0.00 |
DisclosureSEC source: 0001209191-14-062466 · doc4.xml · derivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 1,405 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 05/24/2012. Read SEC document |
| October 06, 2014 Filed Oct 8, 2014 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,405 | $109.75 | $154,198.75 |
DisclosureSEC source: 0001209191-14-062466 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 06, 2014 Filed Oct 8, 2014 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,405 | $63.14 | $88,711.70 |
DisclosureSEC source: 0001209191-14-062466 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 10,595 | $0.00 Strike: $63.14 | $0.00 |
DisclosureSEC source: 0001209191-14-061642 · doc4.xml · derivative · entry 8 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,405 Underlying: Common Stock · 10,595 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 05/24/2012. Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $112.06 | $11,206.00 |
DisclosureSEC source: 0001209191-14-061642 · doc4.xml · nonDerivative · entry 7 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $110.48 | $33,144.00 |
DisclosureSEC source: 0001209191-14-061642 · doc4.xml · nonDerivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $110.48 (range $110.39 to $110.66). Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 695 | $109.51 | $76,109.45 |
DisclosureSEC source: 0001209191-14-061642 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $109.51 (range $109.17 to $110.09). Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,177 | $108.31 | $235,790.87 |
DisclosureSEC source: 0001209191-14-061642 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,095 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $108.31 (range $108.00 to $108.76). Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,942 | $107.56 | $531,561.52 |
DisclosureSEC source: 0001209191-14-061642 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,272 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $107.56 (range $107.00 to $107.98). Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,381 | $106.56 | $253,719.36 |
DisclosureSEC source: 0001209191-14-061642 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,214 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $106.56 (range $106.00 to $106.96). F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 10,595 | $63.14 | $668,968.30 |
DisclosureSEC source: 0001209191-14-061642 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 29, 2014 Filed Sep 30, 2014 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $59.55 | $0.00 |
DisclosureSEC source: 0001209191-14-060234 · doc4.xml · derivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| September 29, 2014 Filed Sep 30, 2014 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $114.75 | $286,875.00 |
DisclosureSEC source: 0001209191-14-060234 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| September 29, 2014 Filed Sep 30, 2014 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,500 | $59.55 | $148,875.00 |
DisclosureSEC source: 0001209191-14-060234 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2014 Filed Sep 26, 2014 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $59.55 | $0.00 |
DisclosureSEC source: 0001209191-14-059946 · doc4.xml · derivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| September 24, 2014 Filed Sep 26, 2014 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $109.75 | $274,375.00 |
DisclosureSEC source: 0001209191-14-059946 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| September 24, 2014 Filed Sep 26, 2014 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,500 | $59.55 | $148,875.00 |
DisclosureSEC source: 0001209191-14-059946 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2014 Filed Sep 23, 2014 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $59.55 | $0.00 |
DisclosureSEC source: 0001209191-14-059297 · doc4.xml · derivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 5,000 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| September 19, 2014 Filed Sep 23, 2014 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $104.75 | $261,875.00 |
DisclosureSEC source: 0001209191-14-059297 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| September 19, 2014 Filed Sep 23, 2014 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $99.75 | $249,375.00 |
DisclosureSEC source: 0001209191-14-059297 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| September 19, 2014 Filed Sep 23, 2014 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,000 | $59.55 | $297,750.00 |
DisclosureSEC source: 0001209191-14-059297 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2014 Filed Sep 9, 2014 22:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $59.55 | $0.00 |
DisclosureSEC source: 0001209191-14-057168 · doc4.xml · derivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 2,500 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| September 05, 2014 Filed Sep 9, 2014 22:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $94.75 | $236,875.00 |
DisclosureSEC source: 0001209191-14-057168 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| September 05, 2014 Filed Sep 9, 2014 22:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,500 | $59.55 | $148,875.00 |
DisclosureSEC source: 0001209191-14-057168 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2014 Filed Aug 1, 2014 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $59.55 | $0.00 |
DisclosureSEC source: 0001209191-14-049983 · doc4.xml · derivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| July 31, 2014 Filed Aug 1, 2014 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $91.36 | $9,136.00 |
DisclosureSEC source: 0001209191-14-049983 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 31, 2014 Filed Aug 1, 2014 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,351 | $89.69 | $210,861.19 |
DisclosureSEC source: 0001209191-14-049983 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $89.69 (range $89.23 to $90.08). Read SEC document |
| July 31, 2014 Filed Aug 1, 2014 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,749 | $88.76 | $155,241.24 |
DisclosureSEC source: 0001209191-14-049983 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,251 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $88.76 (range $88.20 to $89.13). F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 31, 2014 Filed Aug 1, 2014 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,000 | $59.55 | $297,750.00 |
DisclosureSEC source: 0001209191-14-049983 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2014 Filed Jun 3, 2014 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-14-038643 · doc4.xml · derivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2024-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2013 Filed Jun 4, 2013 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $81.54 | $0.00 |
DisclosureSEC source: 0001209191-13-030488 · doc4.xml · derivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2023-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2012 Filed Jun 1, 2012 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $59.55 | $0.00 |
DisclosureSEC source: 0001209191-12-031703 · doc4.xml · derivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2022-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.